Omnio is preparing for taking the company to the next phase
SWEDEN, 5th May, 2023 — Omnio AB, a private biopharmaceutical company developing recombinant plasminogen for chronic non-healing wounds, announces the inauguration of a new board of directors that brings together an outstanding team of seasoned executives in the biotech and life sciences industries. The board of directors comprises of Tomas Eriksson as Chairman of the […]